Pemetrexed and Hyperthyroid - a phase IV clinical study of FDA data

Summary:

Hyperthyroid is reported as a side effect among people who take Pemetrexed (pemetrexed), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Carboplatin, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Hyperthyroid when taking Pemetrexed. It is created by eHealthMe based on reports of 17,478 people who have side effects when taking Pemetrexed from the FDA, and is updated regularly.

What is Pemetrexed?

Pemetrexed has active ingredients of pemetrexed. eHealthMe is studying from 17,491 Pemetrexed users. Check the latest studies of Pemetrexed.

What is Hyperthyroid?

Hyperthyroid is found to be associated with 1,104 drugs and 1,420 conditions by eHealthMe. Check the latest studies of Hyperthyroid.

On Jun, 26, 2026

17,478 people reported to have side effects when taking Pemetrexed.
Among them, 94 people (0.54%) have Hyperthyroid.

Among these 94 people:

How long have people been on Pemetrexed when they have Hyperthyroid? *

What is the gender of people who have Hyperthyroid when taking Pemetrexed? *

female: 52.33 %
male: 47.67 %

What is the age of people who have Hyperthyroid when taking Pemetrexed? *

What are other drugs people take besides Pemetrexed? *

What are other side effects people have besides Hyperthyroid? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 30 people, 31.91%
Fatigue (feeling of tiredness): 16 people, 17.02%
Anaemia (lack of blood): 13 people, 13.83%
Malignant Neoplasm Progression (cancer tumour came back): 12 people, 12.77%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 12 people, 12.77%
Pneumonia: 10 people, 10.64%
Rashes (redness): 10 people, 10.64%
Fever: 8 people, 8.51%
Diarrhea: 8 people, 8.51%
Nausea (feeling of having an urge to vomit): 7 people, 7.45%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 40 people, 42.55%
Lung Neoplasm Malignant (cancer tumour of lung): 16 people, 17.02%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 9 people, 9.57%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 8 people, 8.51%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 6 people, 6.38%
Neoplasm Malignant (cancer tumour): 5 people, 5.32%
Nausea And Vomiting: 4 people, 4.26%
Hepatic Cancer Metastatic (liver cancer - metastatic): 4 people, 4.26%
Metastases To Bone (cancer spreads to bone): 3 people, 3.19%
Headache (pain in head): 3 people, 3.19%

* Approximation only. Some reports may have incomplete information.

Do you take Pemetrexed and have Hyperthyroid?

- Check whether Hyperthyroid is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pemetrexed:

Pemetrexed (17,491 reports)

Hyperthyroid treatments and more:

Hyperthyroid (26,832 reports)

Browse all side effects of Pemetrexed:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperthyroid:

Hyperthyroid (1,104 drugs)

Browse all the conditions that are associated with Hyperthyroid:

Hyperthyroid (1,420 conditions)

Related publications that referenced our studies

Gota V, Kavathiya K, Doshi K, Gurjar M, Damodaran SE, Noronha V, Joshi A, Prabhash K, "High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy", Cancer management and research, 2017 Jan .
Gota V, Kavathiya K, Doshi K, Gurjar M, Damodaran SE, Noronha V, Joshi A, Prabhash K, "High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy", Cancer management and research, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pemetrexed (the active ingredients of Pemetrexed) and Pemetrexed (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.